Chugai stock drops the most since 1977 on disappointing obesity drug data
The stock price of Japan's largest drugmaker sank as much as 20% in Tokyo on Friday, wiping out over $16 billion in market value, or ¥1,458 ($9.89) per share, after the drug's study resulted in lower weight loss and higher rates of nausea and vomiting than anticipated.
Patients on the highest dose of the drug lost 12.4% weight, lower than 15% achieved by patients on a pill developed by rivals Novo Nordisk, wrote Jefferies Japan analysts Stephen Barker and Miyabi Yamanaka.
"With efficacy and safety levels at the lower end of market expectations, Lilly's share price was down 14.5% on the day. Assuming 30% of the ¥14 trillion drop in Lilly's market capitalization corresponds to Chugai royalties, we put related downside risk for Chugai at ¥2,300,' said Citi analyst Hidemaru Yamaguchi.
"The results have not led to a big differentiation with rival pills,' Hiroyuki Matsubara, an analyst at Nomura Securities, wrote in a note.
On Wall Street, Eli Lilly's share prices fell 14% on the news while Novo Nordisk's shares in Denmark jumped 6.7%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Times
5 hours ago
- Japan Times
1 in 55 Japanese middle schoolers abuse over-the-counter drugs, survey shows
A survey conducted by the National Center of Neurology and Psychiatry has found that 1 in 55 middle school students — or 1.8% — abused over-the-counter drugs in the past year. The survey saw 1.5% of male students and 2.0% of female students admitting to having used over-the-counter drugs for the purpose of 'feeling high or changing their mood' and taking more than the prescribed doses or for purposes other than what the medications are meant to treat. Nearly 38,000 students across 124 schools gave valid responses to the survey, which was conducted from September to December last year. Among those who admitted to abusing the drugs, the majority — around 64% — said they got them from pharmacies while a third said they had access to the medications in their own households. Respondents were allowed multiple answers for the question on where they sourced the drugs from. In view of these answers, the study urged pharmacies to pay closer attention when selling over-the-counter drugs to minors. The study found that many of those who have engaged in such abuse tended to be isolated at home or in school, and had experienced psychological problems or other difficulties in their daily lives. The same survey found that 0.07% of middle schoolers had experience using marijuana while 0.13% abused organic solvents; the percentages of respondents who admitted to abusing stimulants and other illegal drugs were both at 0.06%. Across all substances, the abuse rates among respondents last year are lower than those in 2022, most likely due to the fact that lives returned to normal after the COVID-19 pandemic. However, the study warned that an increasingly positive view of marijuana and drug usage among this age group is something to be wary of. The study asked middle schoolers about over-the-counter drugs for the first time last year. The inclusion comes amid a growing problem surrounding the abuse of, and addiction to, over-the-counter drugs such as cough medicine among teenagers and those in their 20s, which have resulted in cases of overdose and hospitalization. The National Center of Neurology and Psychiatry's most recent survey of high schoolers in fiscal 2021 found that 1 in 60 had admitted to abusing over-the-counter drugs. Between 2012 and 2020, cases of addiction involving such drugs across all age groups had experienced a sixfold increase. In recent years, information on how to abuse over-the-counter drugs — such as how much of a certain medication to consume — to achieve certain feelings has become widely available online and spread via social media among the younger generation.
Japan Times
5 hours ago
- Japan Times
Hidden rosters and the legacy of Japan's germ warfare
Katsutoshi Takegami, a retired cafe owner in the city of Komagane, Nagano Prefecture, was cleaning the storehouse of his home seven years ago when he stumbled across a big wooden box. When he opened it, he found a trove of documents, diaries and photo albums kept by his late father, Toshiichi Miyashita, who spent nearly 15 years as a nurse soldier for the Imperial Japanese Army before and during World War II. 'My father didn't look like someone who had spent a long time in the military,' Takegami, 77, recalled. 'I was never slapped or beaten, and he remained calm even when he had drinks. He never once raised his voice.' Intrigued, Takegami obtained Miyashita's military records from the local municipal government. The information he got was astounding: the father had belonged to Unit 1644 in the city of Nanjing in eastern China. Its official responsibility was epidemic control and water purification, but it is believed to have conducted biological weapons research and development in tandem with the infamous Unit 731. A photo album Takegami discovered in his storehouse shows a portrait of his father, Toshiichi Miyashita. | JOHAN BROOKS Together with Katsuo Nishiyama, professor emeritus at Shiga University of Medical Science, Takegami has been investigating the details of these lesser-known sister units to gain a fuller understanding of the Imperial Japanese Army's biological warfare network. In May, the National Archives of Japan disclosed to them rosters containing the names of all personnel who belonged to Unit 1644 , which was based in Nanjing, and Unit 8604, which was based in Guangzhou in southern China. Compiled in 1945, the lists contain information such as the names of every soldier and military civilian in the units, the dates of their assignments and transfers, their addresses, the names of relatives designated as contact persons, the years of their conscription and their dates of birth. Called rusu meibo, the rosters were created by the Imperial Japanese Army to manage records for units stationed abroad and to facilitate communication between those units and the soldiers' families at home. The lists show that some 2,500 people belonged to Unit 1644, quite a large operation comparable to Unit 731's 3,700 members, while Unit 8604 had about 1,000 members. The Imperial Japanese Army had two more similar units — Unit 1855 in Beijing and Unit 9420 in Singapore. A photo album found in the home of Takegami bears a stamp that says "Memories of the Holy War." | JOHAN BROOKS On Aug. 6, Katsutoshi Takegami shows one of many photos left by his father at his home in Komagane, Nagano Prefecture. | JOHAN BROOKS Military records of Toshiichi Miyashita describe detailed activities of his stint in the Imperial Japanese Army, including in the biological warfare unit of Unit 1644. | JOHAN BROOKS After the war, doctors and medical researchers who engaged in human experiments under these units settled into prominent positions in academia and industry. Some are suspected of having obtained advanced medical degrees from top universities using data from the wartime human experiments. Shiro Ishii, leader of Unit 731, was purged from public service by the Allied Occupation and kept a low profile. Ryoichi Naito , a physician who worked under Ishii, went on to establish the Japan Blood Bank, the predecessor of Osaka-based pharmaceutical firm Green Cross Corp. The firm was implicated in a HIV-tainted blood scandal in the 1980s. Tachio Ishikawa, another member who brought back 8,000 slides of pathological samples from Pingfang, became a professor at Kanazawa University. None of them were tried for war crimes, thanks to immunity granted by the United States in exchange for their research data. The disclosure of rosters symbolizes how Japan has lagged behind in its efforts to confront the medical community's war responsibility, which has long remained a taboo, Nishiyama said. Takegami gazes out a glass door at his home in Nagano Prefecture. | JOHAN BROOKS 'Medical education in this country has barely addressed Unit 731,' he said. 'Today, the overwhelming majority of medical students know nothing about it. Without that knowledge, future doctors could end up committing similar acts, or feel they have no choice but to go along. No one in medicine should ever think that way.' Takegami, for his part, is driven more by his interest in his father's life story. The father had no medical background when he joined the military, but he went on to lead a 20- or 30-member team. How Miyashita managed to climb the ranks during the war remains unknown. None of the historical materials Takegami has unearthed and the contacts he has tracked down have uncovered any direct involvement by his father in germ warfare. Not yet at least. 'There's a chance he may have been involved,' he said. 'If he had been, it would prove that, in war, anybody can be forced into committing such acts (of brutality).'
Japan Times
5 hours ago
- Japan Times
South Korean President Lee to visit Japan for summit with Ishiba, Seoul says
South Korean President Lee Jae Myung will visit Japan between Aug. 23 and Aug. 24 and hold a summit with Prime Minister Shigeru Ishiba, Lee's office said at a briefing on Wednesday. The leaders will discuss ways to improve regional peace and boost trilateral cooperation with Washington, Kang Yu-jung, Lee's spokesperson, told reporters. Kang did not specify the date of the summit during Lee's two-day visit. Lee has in the past been critical of efforts by administrations in Seoul to improve ties with Tokyo, though when he met Ishiba for their first summit on the sidelines of a Group of Seven meeting in Canada in June they vowed to deepen the relationship. Ties between the U.S. allies have often been strained, rooted in historical disputes stemming from Japan's colonial rule over the Korean peninsula from 1910 to 1945. Their second summit meeting will also take place as the Asian economic powerhouses grapple with the implications of U.S. tariffs imposed by the administration of U.S. President Donald Trump. Lee's trip to Japan comes just ahead of his visit to the United States, where he is scheduled to hold a summit with Trump on Aug. 25.
